Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $8.06 USD
Change Today -0.12 / -1.47%
Volume 1.6M
AGEN On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 06/1/15 All times are local (Market data is delayed by at least 15 minutes).

agenus inc (AGEN) Key Developments

Agenus Seeks Acquisitions

Agenus Inc. (NasdaqCM:AGEN) is looking for acquisitions. The company has filed a Follow-on Equity Offering and intends to use the net proceeds from this offering to fund our continued research and development initiatives in connection with expanding our product pipeline and for other general corporate purposes, which may include working capital, capital expenditures, and clinical trial expenditures, acquisitions of additional companies or technologies and investments.

Agenus Inc. - Shareholder/Analyst Call

To provide an overview of the company’s proprietary and partnered pipeline, including its antibody platforms and checkpoint modulator programs, its heat shock protein-based vaccine platform and its saponin-based vaccine adjuvant platform and to provide update on its strategic alliances, including those with Incyte and Merck, and its recent strategic acquisition, all within the framework of its overall corporate strategy

Agenus Inc. Announces the Final Results from the Phase 3 Study of Glaxosmithkline’s Malaria Vaccine

Agenus Inc. announced that final results from a large-scale Phase 3 study of GlaxoSmithKline’s malaria vaccine candidate. The study demonstrated a statistically significant reduction against malaria in children who received RTS,S followed by a booster shot of the vaccine at 18 months. RTS,S reduced the number of cases of clinical malaria in young children (aged 5-17 months at first vaccination) by 36%, and in infants (aged 6-12 weeks) by 26% over an average follow-up period of 48 months. This resulted in an average reduction of 1,774 cases of clinical malaria for every 1,000 children vaccinated (aged 5-17 months), and an average reduction of 983 cases of clinical malaria for every 1,000 infants vaccinated over an average 36-month follow-up. Children receiving the vaccine candidate but not a booster dose had lower rates of protection. The study showed that RTS,S averted even more cases of malaria in areas with higher transmission rates. Agenus is eligible for a milestone payment upon approval of RTS,S and royalties from potential commercial sales. QS-21 Stimulon is being evaluated in more than 12 additional vaccine candidates.

Agenus Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Agenus Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported revenue of $3,953,000 compared to $721,000 a year ago. Operating loss was $18,292,000 compared to $9,824,000 a year ago. Net loss attributable to common stockholders of $18,793,000, or $0.28 per share, basic and diluted, compared with a net loss attributable to common stockholders for the first quarter of 2014 of $408,000, or $0.01 per share, basic and diluted. The increase in net loss attributable to common stockholders for the quarter ended March 31, 2015, compared to the net loss attributable to common stockholders for the same period in 2014, was primarily due to non-cash, fair value adjustments of contingent liabilities in 2015 and non-cash, non-operating income during the quarter ended March 31, 2014. The company’s cash burn (cash provided by operating activities excluding up-front fees received and contingent purchase price payments) for the first quarter of 2015 was $10.7 million compared to $10.1 million for the same period in 2014.

Agenus Inc. to Report Q1, 2015 Results on Apr 23, 2015

Agenus Inc. announced that they will report Q1, 2015 results at 9:00 AM, Eastern Standard Time on Apr 23, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AGEN:US $8.06 USD -0.12

AGEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AGEN.
View Industry Companies
 

Industry Analysis

AGEN

Industry Average

Valuation AGEN Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AGENUS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.